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Introduction
Coronary artery disease (CAD) is the leading cause of death worldwide. Approximately 85.6 million American adults suffer from coronary vascular disease and around 30% of all deaths in 2013 were caused by CAD [1] . Although CAD mortality has decreased in recent years, it still remains high. CAD is a multifactorial disease with a complex pathophysiology generated by the combined effects of genes and the environment. Improvement of environmental factors can reduce the rate of CAD prevalence and mortality, but genetic factors remain a problem in CAD. A number of genetic risk factors have been found to predispose individuals to CAD, and the coagulation factor XIII gene, factor XIII, has been extensively studied.
Factor XIII plays an important role in the stabilization of linkages between fibrins and in the pathophysiology of CAD [2, 3] . Factor XIII consists of two types of subunits (A 2 and B 2 ). Factor XIII-A consists of two active A subunits, and factor XIII-B consists of inhibitory/carrier B subunits. Factor XIII-A, which shows transglutaminase activity, strengthens fibrin polymers and protects them from degradation by the fibrinolytic machinery [4] . Many studies have investigated the association between factor XIII-A gene polymorphisms and susceptibility to CAD, especially myocardial infarction (MI). Most studies have focused on one single-nucleotide polymorphism (SNP), which was Val34Leu.
In 2014, two meta-analytical studies were published on the association between factor XIII Val34Leu polymorphism and MI. Chen et al. [5] analyzed 29 studies and showed that factor XIII Val34Leu polymorphism may be associated with the risk of MI, and Wang et al. [6] analyzed 12 studies and showed the same result. However, the association between overall CAD and factor XIII Val34Leu polymorphism has not been analyzed since 2007 [7] . The results of a meta-analysis by Voko et al. [7] suggest that factor XIII Val34Leu polymorphism also affects susceptibility to CAD. In the present study, we performed a meta-analysis of all eligible studies to assess the relationship of factor XIII Val34Leu polymorphism with risk of CAD.
Methods

Identification of eligible studies and data extraction
A literature search was performed for studies examining the association between factor XIII Val34Leu and CAD. The PUBMED and EMBASE citation databases were used to identify available articles in which the factor XIII Val34Leu polymorphism was analyzed in patients with CAD (up to May 2016). The search terms used were as follows: coronary artery disease, myocardial infarction, angina, ischemic heart disease, factor XIII or F13A1, polymorphism, and mutation or variant. References in identified studies were also investigated to identify additional studies not indexed by PUBMED or EMBASE. Studies were included in this meta-analysis if 1) they were case-control studies that determined the distribution of factor XIII Val24Leu polymorphism; 2) they contained original data; and 3) they provided sufficient data to calculate odd ratios (ORs). No restrictions were set on race, language, ethnicity, or geographic area. We excluded the following: 1) studies with overlapping data; 2) studies in which the number of null and wild-type genotypes or alleles could not be ascertained; and 3) studies with only an abstract. We extracted author, year of publication, ethnicity of the study population, demographics, number of cases and controls, and allele frequency of factor XIII Val34Leu polymorphism.
Statistical analysis
Prior to pooling the studies for meta-analysis, the Hardy-Weinberg equilibrium (HWE) was assessed in the control groups of each study. Chisquare test was used to determine whether the observed frequency of genotypes in the control population conformed to HWE expectations. A two-sided p value > 0.05 was considered consistent with the HWE. Statistical analyses were performed using Review Manager 5.3 (The Nordic Cochrane Center, The Cochrane Collaboration, 2014). We performed meta-analyses using 1) allelic contrast, 2) homozygote contrast, and 3) recessive and 4) dominant models. The strength of the association between factor XIII Val34Leu polymorphism and CAD risk was measured by OR and 95% confidence interval (CI). Heterogeneity statistics (I²), overall effect (Z score), and p value were calculated. The effect of heterogeneity was quantified using I², which ranges from 0% to 100% and represents the proportion of between-study variability attributable to heterogeneity rather than chance [8] . The I² values of 25%, 50%, and 75% were nominally considered low, moderate, and high estimates, respectively. With an I² value < 25% or p value of heterogeneity > 0.10, a fixed effect model was selected for Mantel--Haenszel statistics. Otherwise, a random-effect model was used [9] . A funnel plot test was used to assess publication bias and was set at p < 0.10. To evaluate disease-, age-, and sex-specific effects, subgroup analyses were performed based on disease status, age, and sex. Early-onset MI was defined as a cardiac event occurring before the age of 45 years.
Results
Studies included in the meta-analysis
Electronic and manual searches identified 156 applicable studies, and 42 were selected for a full-text review based on the title and abstract details. Three studies were excluded due to duplicate data, and other three studies were excluded because they were meta-analytical studies between factor XIII Val24Leu polymorphism and CAD or MI. A total of 36 studies met the inclusion criteria, and separate comparisons were considered in the present meta-analysis, which included 26,940 cases and 34,694 controls [2, (Table 1) . There were 25 studies performed in European populations, 3 studies in Asian populations, 6 studies in North American populations, 1 study in a South American population, and 1 study in an African population. The present meta-analysis included overall CAD including www.cardiologyjournal.org Table 1 . Characteristics of the case-control studies included in the meta-analysis. MI, unstable angina, coronary sclerosis, cardiac syndrome X, vasospastic angina, etc. A total of 9 studies were performed with patients younger than 45 years; among these, 2 studies also contained patients older than 45 years. Including these 2 studies, a total of 8 studies were performed in patients older than 45 years. Three studies included only male patients, 4 studies only females, and all other included both sexes. Two study analyses were performed separately based on sex.
Meta-analysis of the association between factor XIII Val34Leu polymorphism and coronary artery disease
A summary of the meta-analysis findings concerning associations between factor XIII Val34Leu polymorphism and CAD is provided in Table 2 . The meta-analysis of factor XIII Val34Leu polymorphism showed a significant association between CAD and the Val allele (OR = 1.09, 95% CI 1.03-1.06, p = 0.004; Fig. 1 
Heterogeneity and publication bias
Some heterogeneity was found in the metaanalyses of the factor XIII Val34Leu polymorphisms (Table 2) . For MI risk, there was significant heterogeneity in the Val allele (I 2 = 55%, p = 0.0001; Table 3 ), and the Val/Val vs. Val/Leu + Leu/Leu genotype model (I 2 = 53%, p = 0.0003; Table 3 ). There was also significant heterogeneity in the Val/ /Val vs. Val/Leu + Leu/Leu genotype model in the group of subjects older than 45 years (I 2 = 67%, p = 0.006) and in the Val allele in males (I 2 = 50%, p = 0.09). All studies included in this meta-analysis satisfied the HWE. Publication bias was examined by a funnel plot (Fig. 5) . The shape of the funnel plot was symmetrical, with 18 studies on the left side and 18 studies on the right side.
Discussion
In the current meta-analysis, we investigated the association between factor XIII Val34Leu polymorphism and CAD risk, including 26,940 cases and 34,694 controls. We found that the Val allele and Val/Val genotype showed increased risk of CAD. However, our meta-analyses did not show evidence of an association between factor XIII Val34Leu polymorphism and CAD in any subgroup except MI. These results are in accord with previous meta-analyses [5] [6] [7] . However, Wang et al. [6] suggested that factor XIII Val34Leu polymorphism was significantly associated with MI risk in the subgroup analyses by age and sex.
In the subgroup analysis by disease, the present meta-analysis showed that factor XIII Val34Leu polymorphism affected MI risk, but did not affect risk in CAD without MI, although the CAD without MI group was small (9 studies). CAD involves damage from plaque accumulating on the arterial wall. The buildup of plaque progressively hardens and narrows blood vessels, a process known as atherosclerosis [45] . MI, a severe complication of CAD, is commonly defined as a cardiomyocyte death due to a prolonged ischemia and increase in serum cardiac markers, such as troponin [46] . Both MI and CAD without MI are caused by atherosclerosis, but MI differs from CAD without MI in the existence of cardiac necrosis. We suspect that factor XIII has a function not only in blood coagulation, but also in healing of tissue damage.
Blood coagulation factor XIII has a key role in the terminal phase of the clotting cascade, which contributes to thrombotic events. Factor XII is composed of A and B subunits. Factor XIII is activated by thrombin proteolytically and, in the presence of calcium, dissociation of subunit B [47] . Activated factor XIII induces fibrin cross-linking via noncovalent binding of fibrin polymers. This process finally forms a stable clot that is resistant to shear forces and fibrinolysis [48] . The Val34Leu polymorphism in factor XIII A subunit is located in the activation peptide 3 amino acid residues upstream from the thrombin cleavage site [14] . The 34Leu variant increases activation rate by thrombin, alters fibrin structure in vitro, and influences fibrin cross-linking in vivo [47] . Compared to CAD without MI, a vulnerable plaque is a cruel character of MI. Thus, MI can be protected against by increases in factor XIII due to the 34Leu variant. However, it remains unclear whether the 34Leu variant protects against CAD without MI. The present meta-analysis also showed no association between CAD without MI and factor XIII Val34Leu polymorphisms.
In subgroup analyses by age or sex, there were no associations between CAD and factor XIII Val34Leu polymorphisms. It is possible that the influence of factor XIII Val34Leu polymorphism on CAD might be confounded by the presence of other unidentified causal genes involved in CAD development. Gene-gene interactions should be considered. Fibrinogen is an independent predictor of atherosclerotic disease including MI [49] . The factor XIII A 34Val allele is associated with an increase in fibrinogen concentrations, as is the fibrinogen Aa 312Ala allele. Fibrinogen Aa Thr312Ala polymorphism is also associated with fibrinogen concentration. High fibrinogen concentrations lead to formation of a fibrin clot, which is highly thrombogenic [50] . In addition, factor XIII B His95Arg polymorphism is associated with development of MI when inherited with factor XIII A Val34Leu polymorphism. The Arg95 allele reduces MI risk in the presence of the Leu34 allele [33] . Factor II 20210A and factor V leiden variants are also associated with MI risk, and Tyr2047Phe and Pro564Leu variants in the factor XIII A gene are associated atherosclerotic disease [18, 30] . Gene-environment interaction should also be considered. Fibrinogen concentrations are associated with smoking, insulin resistance and physical activity [50] . The 34Leu allele is related to taking estrogen [48] .
In recent years, another aspect of factor XIII has been identified in addition to blood coagulation. Factor XIII influences wound healing in several tissues, including cardiomyocytes, by exerting multiple plasma and cellular functions. Moreover, the proangiogenic function of factor XIII is directed by the interaction of vascular endothelial growth factor receptor 2 and integrin aVb 3 on the cell membrane [51] . Certain studies showed that low factor XIIIA level correlated with a poor prognosis with regard to MI [52, 53] . Therefore, MI could be differently affected by this function of factor XIII compared to CAD without MI.
The present meta-analysis has several strengths. It included the largest number of studies. Previous meta-analyses included primarily Caucasians, however this meta-analysis contained other ethnicities including Asians. In addition, we used real gene polymorphism data in the meta-analysis rather than adjusted ORs, which could reduce the bias arising from adjustment.
Limitations of the study
As with any meta-analysis, there are a number of limitations that need to be considered. First, the proportion of studies with MI was too large. Among 36 studies, MI was included in 31 studies, which could overestimate the association between gene polymorphism and overall CAD. Second, although we sought to study gene effects in all ethnic groups, the majority of studies were conducted in Caucasian populations. Third, each study was not analyzed using uniform inclusion and exclusion criteria. Each CI -confidence interval; L -factor XIII Leu; OR -odds ratio; R -random effects model; V -factor XIII Val study also differently defines MI, even though each definition of MI was mostly based on ischemic symptom, change of electrocardiography, and elevation of cardiac biomarkers. Fourth, in addition to Val34Leu polymorphism, the factor XIII A gene includes other genetic variants, such as tyr204Phe and Pro564Leu [18] . Fifth, due to the lack of the original data of the eligible studies, the evaluation of the effects of gene-gene or gene-environment interactions was limited, as well as the ability to perform subgroup analyses by age and sex. Sixth, all included studies were retrospective case-control studies, thus, we cannot exclude the possibility of undetected bias. Finally, publication bias is an important feature of meta-analyses, which we attempted to minimize by including studies in all languages.
Conclusions
In conclusion, this meta-analysis showed that factor XIII Val34Leu polymorphism was associated with CAD risk, especially with MI, but not with CAD without MI. In addition, age or sex did not affect the relationship between factor XIII Val34Leu polymorphism and CAD risk. However, some significant limitations exist in the interpretation of the result and the present meta-analysis should be interpreted with caution. www.cardiologyjournal.org
